Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

RNA Helicase p68 Deploys β-Catenin in Regulating RelA/P65 Gene Expression

View through CrossRef
RelA/p65 is a crucial member of NF-κB signaling pathway. Limited knowledge prevails on the mechanistic insights of RelA gene regulation. RNA helicase p68 acts as a &nbsp;transcriptional coactivator of several oncogenic transcription factors. Here we report, a &nbsp;novel mechanism of alliance between p68 and β-catenin in regulating the expression of &nbsp;RelA. p68, β-catenin and RelA proteins were found to bear strong positive correlation &nbsp;in normal and colon carcinoma patient samples. Both p68 and β-catenin increased &nbsp;RelA mRNA and protein expression. p68 and Wnt3a elevated RelA promoter activity&nbsp;and p68 was perceived to occupy RelA promoter with β-catenin at the TCF4/LEF (TBE) sites. p68 and β-catenin alliance positively modulated the expression of signature NF-βB target genes. Enhanced NF-βB target gene expression by p68 was corroborated by &nbsp;findings in clinical samples and mice colorectal allograft models. This study unravels &nbsp;novel modes of p68-mediated oncogenesis, marking it a potential target for therapy.<br><br>Funding: This work is supported by grants received from DST {Nano Mission programme (SR/NM/NS-1058/2015), SERB (EMR/2017/001183)} and CSIR, Govt. of India to Dr. Mrinal K Ghosh.<br><br>Declaration of Interest: The authors declare no competing interests.<br><br>Ethical Approval: All clinical and ethical regulations were followed for collecting the samples, including patient consent and with formal approval from the ethical committee of both CSIR-IICB and Park Clinic. All animal care and experimentation were conducted according to the CPCSEA guidelines; with approval of the animal ethics committee at CSIR-Indian Institute of Chemical Biology.
Title: RNA Helicase p68 Deploys β-Catenin in Regulating RelA/P65 Gene Expression
Description:
RelA/p65 is a crucial member of NF-κB signaling pathway.
Limited knowledge prevails on the mechanistic insights of RelA gene regulation.
RNA helicase p68 acts as a &nbsp;transcriptional coactivator of several oncogenic transcription factors.
Here we report, a &nbsp;novel mechanism of alliance between p68 and β-catenin in regulating the expression of &nbsp;RelA.
p68, β-catenin and RelA proteins were found to bear strong positive correlation &nbsp;in normal and colon carcinoma patient samples.
Both p68 and β-catenin increased &nbsp;RelA mRNA and protein expression.
p68 and Wnt3a elevated RelA promoter activity&nbsp;and p68 was perceived to occupy RelA promoter with β-catenin at the TCF4/LEF (TBE) sites.
p68 and β-catenin alliance positively modulated the expression of signature NF-βB target genes.
Enhanced NF-βB target gene expression by p68 was corroborated by &nbsp;findings in clinical samples and mice colorectal allograft models.
This study unravels &nbsp;novel modes of p68-mediated oncogenesis, marking it a potential target for therapy.
<br><br>Funding: This work is supported by grants received from DST {Nano Mission programme (SR/NM/NS-1058/2015), SERB (EMR/2017/001183)} and CSIR, Govt.
of India to Dr.
Mrinal K Ghosh.
<br><br>Declaration of Interest: The authors declare no competing interests.
<br><br>Ethical Approval: All clinical and ethical regulations were followed for collecting the samples, including patient consent and with formal approval from the ethical committee of both CSIR-IICB and Park Clinic.
All animal care and experimentation were conducted according to the CPCSEA guidelines; with approval of the animal ethics committee at CSIR-Indian Institute of Chemical Biology.

Related Results

Abstract 209: Identification of β-catenin lysine 394 as a novel charge button and ubiquitination site by Rad6B
Abstract 209: Identification of β-catenin lysine 394 as a novel charge button and ubiquitination site by Rad6B
Abstract Clinical evidence suggests that β-catenin accumulation in breast cancer is associated with poor prognosis. Accumulation of β-catenin occurs even though acti...
RelB, Together with Rela, Maintains the Cellular Survival In Chronic Lymphocytic Leukemia
RelB, Together with Rela, Maintains the Cellular Survival In Chronic Lymphocytic Leukemia
Abstract Abstract 3583 RelA, a classical NF-κB subunit, has been shown to function critically in cellular survival and drug-resistance of B-cell chron...
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Abstract Abstract 1851 Background: The proteasome inhibitor Bortezomib (Bz) shows significant activity in Multipl...
The Hippo effector TAZ cooperates with oncogenic β-catenin in experimental and human hepatoblastoma development
The Hippo effector TAZ cooperates with oncogenic β-catenin in experimental and human hepatoblastoma development
Abstract Backgrounds: Hepatoblastoma (HB) is the most common pediatric liver tumor. Though Wnt/β-catenin and Hippo cascades are implicated in HB development, there is no st...
Detecting RNA–RNA interactome
Detecting RNA–RNA interactome
AbstractThe last decade has seen a robust increase in various types of novel RNA molecules and their complexity in gene regulation. RNA molecules play a critical role in cellular e...
Microrna Regulation of Nodule Zone-Specific Gene Expression In Soybean
Microrna Regulation of Nodule Zone-Specific Gene Expression In Soybean
Nitrogen is a paramount important essential element for all living organisms. It has been found to bea crucial structural component of proteins, nucleic acids, enzymes and other ce...
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract Introduction Variant calling based on DNA samples has been the gold standard of clinical testing since the advent of Sanger sequencing. The u...

Back to Top